A review of peritoneal mesothelioma at the Washington Cancer Institute

Surgical Oncology Clinics of North America

Volumn 12, Issue 3, 2003, Pages 605-621

  Sugarbaker, Paul H ^a   Welch, Laura S ^b   Mohamed, Faheez ^a   Glehen, Olivier ^c  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b The Center for Construction Research and Training   (United States)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; MITOMYCIN C; PACLITAXEL;

ADULT; AGE; CANCER CENTER; CANCER SURGERY; CANCER SURVIVAL; CHEMOSURGERY; CYTOREDUCTIVE SURGERY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PERITONEUM MESOTHELIOMA; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; REVIEW; SEX DIFFERENCE; SURVIVAL TIME; TUMOR VOLUME; UNITED STATES;

EID: 0042744851     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00045-0     Document Type: Review

References (34)

1. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-8.
2. Shridhar KS, Doria R, Raub WA Jr, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70:2969-79.
3. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
4. Ascensio JA, Goldblatt P, Thomford NR. Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature. Arch Surg 1990;125:477-81.
5. Wagner JC, Sleegs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71.
6. Peterson JT Jr, Greenberg SD, Buffler P. Non-asbestos-related malignant mesothelioma. A review. Cancer 1984;54:951-60.
7. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. IARC Monogr Eval Carcinog Risk Chem Man 1977;14:1-106.
8. Acherman YIZ, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of mesothelioma. Tumor 2003 (in press).
9. Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 2000;17:260-71.
10. Gilks B, Hegedus C, Freeman H, Fratkin L, Churg A. Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 1988;61:2019-21.
11. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982; 96:746-55.
12. Maurer R, Egloff B. Malignant peritoneal mesothelioma after cholangiography with Thorotrast. Cancer 1975;36:1381-5.
13. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357: 444-5.
14. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587-93.
15. Sugarbaker PH, Acherman YIZ, Gonzales-Moreno S, Ortega-Perez G, Stuart A, Marchettini P, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol 2002;29:51-61.
16. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston (MA): Kluwer Academic Publishers; 1996. p. 359-74.
17. Alcorn KW, Yan H, Shmookler BM, et al. Differential diagnosis of the simultaneous occurrence of colon carcinoma and peritoneal mesothelioma by immunohistochemistry. Surg Rounds 2000;23:411-7.
18. Jacquet P, Sugarbaker PH. Influence of wound healing on gastrointestinal cancer recurrence. Wounds 1995;7:40-7.
19. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58.
20. Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre AY, Rembeaux A, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988;93:159-62.
21. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;119:55-7.
22. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997;52:507-12.
23. Neumann V, Muller KM, Fisher M. Peritoneal mesothelioma - incidence and etiology. Pathologe 1999;20:169-76.
24. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70:6-12.
25. Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6:582-90.
26. Loggie BW, Fleming RA, McQuellon RP, Russel GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67:999-1003.
27. Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women. Cancer 2002;94:378-85.
28. Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinico-pathological study of nineteen true mesothelial neoplasms other than adenomatoid tumors, multicystic mesothcliomas and localized fibrous tumors. Am J Surg Pathol 1995;19:1124-37.
29. Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002;20:694-8.
30. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71-6,
31. Glehen O, Mithieux F, Osinski D, Beaujard AC, Freyer G, Gertsch P, et al. Digestive surgery combined with peritonectomy procedures and intraperitoneal chemo-hyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799-806.
32. Markman M. Intraperitoneal therapy in the management of peritoneal mesothelioma. J Inf Chemother 1993;3:50-2.
33. Markman M, Kelsen D. Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Reg Cancer Treat 1989;2:49-53.
34. Zidar BL, Green S, Pierce HI, Roach RW, Balcersak SP, Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988:223-4.